SAGE Therapeutics Inc. (SAGE)

146.01
NASDAQ : Health Technology
Prev Close 147.04
Day Low/High 145.41 / 149.26
52 Wk Low/High 59.57 / 195.97
Avg Volume 416.60K
Exchange NASDAQ
Shares Outstanding 46.66M
Market Cap 6.86B
EPS -7.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sage Therapeutics Announces The Lancet Publishes Integrated Data From Pivotal Trials For Brexanolone Injection In Postpartum Depression

Sage Therapeutics Announces The Lancet Publishes Integrated Data From Pivotal Trials For Brexanolone Injection In Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced The Lancet has published an integrated analysis across three,...

Sage Therapeutics Announces Second Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces Second Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the second quarter...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Present At Canaccord 38th Annual Growth Conference

Sage Therapeutics To Present At Canaccord 38th Annual Growth Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Canaccord 38th Annual Growth...

Sage Therapeutics To Report Second Quarter 2018 Financial Results On Tuesday, August 7, 2018

Sage Therapeutics To Report Second Quarter 2018 Financial Results On Tuesday, August 7, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018, the Compensation Committee of Sage's Board of...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sage Therapeutics, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sage Therapeutics, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

NEW YORK, June 25, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Sage...

Sage Therapeutics And Shionogi & Co., Ltd., Enter Strategic Collaboration To Develop And Commercialize SAGE-217 For MDD And Other Indications In Japan, Taiwan And South Korea

Sage Therapeutics And Shionogi & Co., Ltd., Enter Strategic Collaboration To Develop And Commercialize SAGE-217 For MDD And Other Indications In Japan, Taiwan And South Korea

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co.

Jim Cramer: Investors Pull Into the FANG Rest Stop

Jim Cramer: Investors Pull Into the FANG Rest Stop

When rotations slow or pause, investors return to the new classics.

Sage Announces Pivotal Phase 3 Trial Status For SAGE-217 In Major Depressive Disorder And Postpartum Depression Based On FDA Breakthrough Therapy Meeting

Sage Announces Pivotal Phase 3 Trial Status For SAGE-217 In Major Depressive Disorder And Postpartum Depression Based On FDA Breakthrough Therapy Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced its expedited development plan for SAGE-217 following a Breakthrough...

Sage Therapeutics To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Sage Therapeutics To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 39 th Annual Global...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 1, 2018, the Compensation Committee of Sage's Board of...

Noteworthy Wednesday Option Activity: SAGE, SAM, EXPR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sage Therapeutics Inc , where a total of 1,736 contracts have traded so far, representing approximately 173,600 underlying shares. That amounts to about 45.2% of SAGE's average daily trading volume over the past month of 383,805 shares.

Sage Therapeutics To Present At Bernstein's 34th Annual Strategic Decisions Conference

Sage Therapeutics To Present At Bernstein's 34th Annual Strategic Decisions Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at Bernstein's 34 th Annual Strategic...

Sage Therapeutics To Present At Bank Of America Merrill Lynch 2018 Health Care Conference

Sage Therapeutics To Present At Bank Of America Merrill Lynch 2018 Health Care Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that members of the Sage management team will participate in a fireside...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics Announces First Quarter 2018 Financial Results And Provides Update On Pipeline And Progress Toward Launch Readiness

Sage Therapeutics Announces First Quarter 2018 Financial Results And Provides Update On Pipeline And Progress Toward Launch Readiness

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter...

Sage Therapeutics To Report First Quarter 2018 Financial Results On Thursday, May 3, 2018

Sage Therapeutics To Report First Quarter 2018 Financial Results On Thursday, May 3, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression

Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the Company has submitted a New Drug Application (NDA) to the U.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on April 2, 2018, the...

Sage Therapeutics To Present At Cowen & Co. 38th Annual Health Care Conference

Sage Therapeutics To Present At Cowen & Co. 38th Annual Health Care Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on March 1, 2018, the...

Sage Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results And Provides Pipeline Update

Sage Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results And Provides Pipeline Update

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and...

Sage Therapeutics To Report Fourth Quarter And Full Year 2017 Financial Results On Thursday, February 22, 2018

Sage Therapeutics To Report Fourth Quarter And Full Year 2017 Financial Results On Thursday, February 22, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference...

Sage Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference

Sage Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a...